Why are physicians not persuaded by scientific evidence? A grounded theory interview study by Sekimoto, Miho et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Health Services Research
Open Access Research article
Why are physicians not persuaded by scientific evidence? A 
grounded theory interview study
Miho Sekimoto*1, Yuichi Imanaka1, Nobuko Kitano1, Tatsuro Ishizaki1 and 
Osamu Takahashi2
Address: 1Department of Healthcare Economics and Quality Management, Kyoto University Graduate School of Medicine, Yoshida Konoe-cho, 
Sakyo-ku, Kyoto, 606-8501, Japan and 2Department of General Medicine and Clinical Epidemiology, Kyoto University Graduate School of 
Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
Email: Miho Sekimoto* - msekimot@pbh.med.kyoto-u.ac.jp; Yuichi Imanaka - imanaka@pbh.med.kyoto-u.ac.jp; 
Nobuko Kitano - okkrbnnn72@fiberbit.net; Tatsuro Ishizaki - tatsuro@pbh.med.kyoto-u.ac.jp; Osamu Takahashi - bur-kyt@umin.ac.jp
* Corresponding author    
Abstract
Background: The government-led "evidence-based guidelines for cataract treatment" labelled
pirenoxine and glutathione eye drops, which have been regarded as the standard care for cataracts
in Japan, as lacking evidence of effectiveness, causing great upset among ophthalmologists and
professional ophthalmology societies. This study investigated the reasons why such "scientific
evidence of treatment effectiveness" is not easily accepted by physicians, and thus, why they do not
change their clinical practices to reflect such evidence.
Methods: We conducted a qualitative study based on grounded theory to explore physicians'
awareness of "scientific evidence" and evidence-supported treatment in relation to pirenoxine and
glutathione eye drops, and to identify current barriers to the implementation of evidence-based
policies in clinical practice. Interviews were conducted with 35 ophthalmologists and 3 general
practitioners on their prescribing behaviours, perceptions of eye drop effectiveness, attitudes
toward the eye drop guideline recommendations, and their perceptions of "scientific evidence."
Results: Although few physicians believed that eye drops are remarkably effective, the majority of
participants reported that they prescribed eye drops to patients who asked for them, and that such
patients accounted for a considerable proportion of those with cataracts. Physicians seldom
attempted to explain to patients the limitations of effectiveness or to encourage them to stop
taking the eye drops. Physicians also acknowledged the benefits of prescribing such drugs, which
ultimately outweighed any uncertainty of their effectiveness. These benefits included economic
incentives and a desire to be appreciated by patients. Changes in clinical practice were considered
to bring little benefit to physicians or patients. Government approval, rarity of side effects, and low
cost of the drops also encouraged prescription.
Conclusion: Physicians occasionally provide treatment without expecting remarkable therapeutic
effectiveness, as exemplified by the use of eye drops. This finding highlights that scientific evidence
alone cannot easily change physicians' clinical practices, unless evidence-based practices are
accepted by the general public and supported by health policy.
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Background
Evidence-based Medicine (EBM) is increasingly attracting
worldwide attention in public policy [1], resulting in the
mass production of evidence-based clinical guidelines
[2,3]. The paradigm of EBM was introduced to Japan in
the mid-1990s and has quickly gained immense popular-
ity among healthcare professionals. The Japanese govern-
ment has organized ad hoc groups to develop evidence-
based, clinical guidelines targeting 23 high priority dis-
eases. However, recent opinions tend to be critical of
EBM, arguing that it has not been adequately integrated
into Japanese medical practices [4]. Some evidence-based
guidelines have come under attack, including those estab-
lished for cataract treatment. Released in 2003, the guide-
lines pointed out that no scientific evidence supports the
effectiveness of pirenoxine and glutathione eye drops,
which are commonly prescribed to treat the condition.
Several newspapers reported that healthcare providers are
prescribing ineffective eye drops in order to increase the
number of patient consultations. Understandably, this
media coverage caused much distress among ophthalmol-
ogists and professional ophthalmology societies in Japan
[5].
Although EBM advocates argue that misunderstandings
surrounding EBM have created this situation, it is also
important to understand the dynamics that govern physi-
cians' acceptance or rejection of evidence-based clinical
guidelines. We investigated physicians' attitudes and
opinions regarding the Evidence-based Clinical Guide-
lines for Cataract Treatment, and attempted to identify the
reasons why physicians sometimes conduct clinical prac-
tices that are not supported by scientific evidence. This
study focused on physicians' prescribing behaviours, per-
ceptions of pirenoxine and glutathione eye drop effective-
ness, attitudes toward the guideline's recommendations,
and attitudes toward "scientific evidence." Pirenoxine and
glutathione eye drops are commonly prescribed to an esti-
mated 1.3 million cataract patients in Japan. This study
also investigated why the guidelines were so controversial
among Japanese ophthalmologists, and whether they
have influenced physicians' practices. Such exploration is
anticipated to reveal the reasons why evidence-based prac-
tice has been difficult to integrate into clinical practices in
Japan, as well as in other countries.
Methods
Background data regarding the use of pirenoxine and 
glutathione eye drops
Pirenoxine eye drops were first approved by the govern-
ment in 1958 as a preventive drug for the initial stage of
senile cataract. This approval was based on three studies
[6-8], which used animal experiments and patho-physio-
logical principles to conclude that eye drops have a pre-
ventative effect against senile cataract. The evidence-based
guidelines reviewed data relevant to the treatment of cata-
ract, recommending surgery as the definitive treatment
and determining the effectiveness of eye drops to be
uncertain (See Appendix). Based on a systematic literature
review, the guidelines identified three clinical trials con-
ducted in Japan that investigated the effectiveness of
pirenoxine and glutathione eye drops, and concluded that
neither demonstrated effectiveness [9-11]. Although these
clinical trials reported that lens opacity was better in the
eye drop group compared to its control, this assessment
was based on a subjective measurement. There were no
double-blind studies to evaluate the eye drops in terms of
visual acuity and no adverse effects were reported in the
trials.
Participants and methods
This study used Grounded Theory – an established quali-
tative method of categorizing empirically collected data,
building a general theory to fit the data, and guiding data
collection and analysis [12,13]. We initially constructed a
maximum variety sample of 30 ophthalmologists to
reflect a range of practitioner characteristics that could
influence prescribing behaviours and opinions of the
guideline [See Table 1]. In order to minimize regional
bias, physicians were selected from both eastern and west-
ern Japan. Participants were recruited from different med-
ical settings such as academic-affiliated hospitals and
private practice or community hospitals, and represented
a wide range of career stages to minimize bias derived
from differential incentives for prescribing eye drops. We
asked a research company to recruit participants via tele-
phone from their database. A total number of 346 physi-
cians were contacted.
In Japan, the majority of cataract patients are treated by
ophthalmologists; however, some patients consult gen-
eral practitioners (GP) for repeat prescriptions. This is par-
Table 1: Characteristics of 30 ophthalmologists in the maximum 
variety sample
No of ophthalmologists
Gender
Male 24
Female 6
Site of practice
Teaching hospital 9
Private practice 14
Community hospital 7
Area
Western Japan 21
Eastern Japan 9
Age
Younger than 40 11
40–49 13
Older than 50 7BMC Health Services Research 2006, 6:92 http://www.biomedcentral.com/1472-6963/6/92
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ticularly the case in rural areas where no specialist
ophthalmology services are available. In this situation,
patients initially consult urban ophthalmologists and
then follow up with a local GP to receive their medication.
Therefore, we interviewed an additional sample of three
general practitioners. Another five ophthalmologists were
interviewed to uphold the grounded theory principle of
selection guided by the emerging analysis. The study pro-
tocol was approved by the Research Ethics Committee of
the Kyoto University Graduate School of Medicine.
Data collection and analysis
We conducted face-to-face, open-ended interviews at par-
ticipants' clinics using a structured interview guide. Ques-
tions related to pirenoxine and glutathione eye drops
included: frequency of prescription, perceptions about
effectiveness, explanations to patients about their effec-
tiveness, implementation of the related clinical guideline
(see Appendix), and how the guidelines influenced their
practices. One question related to opinions about the
application of the EBM paradigm into health policy.
When necessary, we added further questions to elucidate
participants' perceptions of EBM.
Five trained interviewers conducted face-to-face inter-
views with participants and MS conducted eight inter-
views with the additional sample. Participants were
encouraged to speak freely, discuss personally important
issues, and to support their responses with examples from
clinical practice, research, and/or policy when appropri-
ate. All interviews were audio-taped and transcribed ver-
batim. We used constant comparative analysis to interpret
the data [13]. MS and OT developed the structured inter-
view guide, while MS and NK analyzed all interviews. All
authors contributed to the analysis independently and
discrepancies were discussed until final agreement. We
scrutinized each interview line by line to identify main
categories and concepts, which were then compared
across scripts and with established concepts in published
literature. Data collection and analyses were iterative, with
new data used to assess the integrity of the developing
analysis.
Results
Physicians reported that, in general, patients anticipated
the effectiveness of the eye drops and considered them to
be the standard of treatment for cataracts. Physicians esti-
mated prescription frequencies ranging from fewer than
two in ten to "almost all" patients, many of which
demanded such prescriptions. Approximately half of the
participants conducted monthly follow-up visits with
such patients, while the other half considered three-
month intervals to be adequate.
Opinions regarding the effectiveness of the eye drop
Most physicians reported never having witnessed objec-
tive effectiveness of cataract eye drops in their clinical
practice. Only one ophthalmologist claimed that eye
drops were definitely effective in approximately 20–30
percent of patients, recounting his experience with a
patient who had been able to avoid surgery with these
medications. Nevertheless, 23 physicians did not rule out
the effectiveness of these drugs, citing cases in which
symptoms did not progress when these medications were
administered on a long-term basis, and that that patients
were more willing to maintain contact with them in order
to continue taking the drops.
The grounds for perceived "true effectiveness" were gov-
ernmental approval of the drops, medical properties
based on physiology, bench research or "first principles."
The majority of participants believed that the lack of stud-
ies proving the effectiveness of the drops was not necces-
sarily proof of ineffectiveness. Three reasons were put
forward for this position: 1) difficulty assessing the effec-
tiveness of preventative medications using conventional
epidemiological methods; 2) psychological benefits,
which are not generally measured in clinical epidemiol-
ogy; and 3) the lack of large clinical trials proving the inef-
fectiveness of the drugs.
Eight ophthalmologists refuted the effectiveness of such
medications outright. However, such statements were pri-
marily based on clinical experience rather than on "scien-
tific evidence." GPs generally had no firm opinion
regarding the effectiveness of the drops. Despite that GPs
did not think that such medications had remarkable
effects, they believed them to be clinically effective since
they are widely used by experts and frequently requested
by patients.
All but one physician agreed that eye drops are necessary
to some patients for psychological comfort. Although some
participants considered this effect to be spurious, they still
argued that such placebo effects should be validated.
Attitudes and behaviours in prescribing the eye drops
None of the participants adopted a clinical practice in
which they refused to prescribe eye drops to patients. Phy-
sicians' prescription behaviours were broadly divided into
four categories; (1) automatic or active prescription, (2)
passive prescription, (3) prescription based on patient
delegation, and (4) avoiding prescription.
Seventeen ophthalmologists automatically prescribed the
eye drops. Eleven physicians reported passive prescription
in response to patients' requests. They did not believe
them to be clinically effective, and never recommended
them out of their own volition. However, when patientsBMC Health Services Research 2006, 6:92 http://www.biomedcentral.com/1472-6963/6/92
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requested these preparations, they prescribed them with-
out discussion. GPs who had no opinion about the effec-
tiveness of the drops also prescribed them automatically
when requested. That is their role was merely to write a
prescription based on a patient's request, rather than to
make a formal prescribing decision. Since patients had
already been prescribed the drug by an ophthalmologist,
the GPs felt they were not in a position to challenge
patients' preferences or beliefs, considering it safer to fol-
low the ophthalmologist's advice. In this respect, GPs'
attitudes toward prescription were passive, although their
prescription behaviour was automatic.
Six physicians, five of whom practised in teaching hospi-
tals, delegated the prescription decision to patients. These
participants tended to vacillate in their opinions of the
effectiveness of these drops; they did not observe remark-
able clinical effects, but recognised that the preparations
contain active ingredients and appreciated their psycho-
logical effects. Lacking a definitive opinion on the drugs'
effectiveness, these participants preferred to provide infor-
mation and allow their patients to make the ultimate deci-
sion.
All but two ophthalmologists stated that they usually dis-
cussed uncertainties or limitations regarding the effective-
ness of the medications with their patients. Among
participants who shared this perspective, however, expla-
nations varied widely. While some affirmed the effective-
ness, even if not emphasizing it, many subtly implied that
the drops helped prevent the progression of cataracts. An
ophthalmologist who believed the drops to be effective
reported that he often encouraged patients to use them,
citing cases in which the drug had dramatic effects.
Another ophthalmologist, who automatically prescribed
the drugs, encouraged patients to use them by displaying
an image of the cornea and then advoctaing that they
maintain control over the illness. Eight ophthalmologists
reported trying not to use expressions that refute the effec-
tiveness of the eye drops, regardless of their own beliefs.
Four encouraged patients who eagerly used the drugs;
their explanations included, "Your efforts will be paid
off," or "At this point, we cannot say these eye drops are
ineffective, but we may know in the future." Four physi-
cians tried to dissuade patients from requesting these
drugs by giving negative explanations of their effective-
ness. As reported below, this approach was sometimes
successful:
Ophthalmologist:"For the last few years, I have usually said
threateningly to a patient who requests these eye drops, 'You
cannot discontinue them once you have started. Because the
effectiveness is subtle, they lose their strength if used intermit-
tently. Do you think you can continue to apply these drops sev-
eral times a day, every day, from now on?' Putting it that way,
patients in my neighbourhood are quick to understand and few
still insist on the eye drop. But my colleagues tell me that such
understanding patients are seldom encountered in their local-
ity".
Knowledge of and attitudes toward the paradigm of 
evidence-based medicine (EBM)
Twenty-eight participants reported being familiar with or
had encountered the term "EBM." However, only seven
agreed with the paradigm. The most difficult principles to
support were "assessing treatment effectiveness based
mainly on clinical research," "assessing effectiveness
based on its magnitude," and "assessing treatment effec-
tiveness in a patient group, rather than in individual
patients." These 28 ophthalmologists reported that
although the guidelines mention an absence of scientific
evidence supporting drug effectiveness of eye drops, they
believed that their effectiveness or ineffectiveness has yet
to be proven. Opinions of physicians who supported the
EBM paradigm were divided in terms of the drugs' effec-
tiveness. Some believed that a lack of evidence proving
effectiveness is equivalent to the drugs being ineffective,
while others thought that their effectiveness has yet to be
refuted.
When we asked participants whether they considered sci-
entific evidence of effectiveness in decisions to prescribe a
drug, 27 replied that this is not possible in the case of cat-
aract eye drops, because there is currently no solid conclu-
sion regarding drug effectiveness. Five also stated that as
no alternative medications exist for cataracts, the only
remaining option is to treat patients conservatively with
the eye drops until surgery is necessary. They assumed that
they had to provide something for patients who consulted
them, regardless of scientific evidence.
Seven physicians reported feeling more comfortable using
medications with proven effectiveness. However, they
would still use the drugs even in the absence of such sci-
entific evidence, particularly if only one treatment is avail-
able. Evidence of effectiveness was important only when
needing to compare multiple treatment options.
One physician expressed concern that EBM methodology
is not suitable to assess the "psychological effects" of a
drug:
Ophthalmologist: "I think the assessment of treatment effec-
tiveness based on EBM fails to consider the view of patients
diagnosed with cataract who feel tremendously insecure if no
action (such as applying an eye drop) is performed. Although
patients' anxieties may be considered to be unscientific in EBM,
I think it's an important issue that clinicians cannot ignore."BMC Health Services Research 2006, 6:92 http://www.biomedcentral.com/1472-6963/6/92
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Maintaining the physician-patient relationship
Prescribing the eye drops was acknowledged as one of the
most important factors in maintaining the physician-
patient relationship. Regardless of beliefs about their
effectiveness, ophthalmologists agreed that the primary
objective of the prescription was to satisfy patients who
demand them. One ophthalmologist stated that patient
satisfaction is one of the most important duties of a phy-
sician, and that drugs that do neither harm nor good are
sometimes useful for that purpose. Ten ophthalmologists
reported using the eye drop as a tool to maintain a good
relationship with patients and to establish their reputa-
tion as a responsible physician.
Physicians noted that some patients consider it important
to receive the standard of care for cataract treatment.
Therefore, they believed that not prescribing the drug
would lead to patient dissatisfaction and distrust. One
ophthalmologist stated:
Ophthalmologist: "I had an experience with one patient to
whom I didn't prescribe the drug, after explaining that it's sup-
posed to be ineffective. When his symptoms got worse, he came
to me and said, 'I wonder if my cataract progressed because you
didn't give me the drug.' He didn't appreciate my explanation
that the effectiveness of these eye drops is uncertain or that
progress of the illness mostly depends on characteristics of the
individual patient. Consequently, I felt that I had to prescribe
the drug."
Another ophthalmologist explained that he worries that
patients do not appreciate physicians who faithfully fol-
low EBM guidelines and not prescribe the eye drops. Con-
versely, an ophthalmologist who described herself as a
"low prescriber" reported experiencing little difficulty in
convincing patients not to use the drops. Most patients
were persuaded by her explanation that the eye drops are
useless and did not further request the drug. However, she
also reported prescribing the drugs on occasion to some
patients who continued to demand them. She believed
that persuaded patents did not visit other ophthalmolo-
gists in order to obtain the drugs, but rather consult her
for routine check-ups every six months to one year.
Another GP stated that successful interactions with
patients are dependent upon a trusting relationship
between patient and provider:
GP: "Although I am not an expert, when I tell them that the
effectiveness of these eye drops is uncertain, quite a few patients
who trust me may take my advice seriously. If we doctors fully
understand the paradigm of EBM, and clearly explain that the
eye drop sometimes has side effects and is not very effective,
we'll succeed in persuading patients. But at the same time, we
must be accountable to them for the reasons why we have pre-
scribed these drugs for so long."
Economic incentives of prescribing the eye drops
Two clinic-owning ophthalmologists who did not provide
surgical treatment at their clinics reported that they would
have financial difficulties if they did not prescribe these
eye drops; however, they insisted that moneymaking was
not the primary reason for this practice. One ophthalmol-
ogist who had recently purchased his clinic described the
economic incentive in prescribing the eye drops.
Ophthalmologist: "Before I owned my clinic, I seldom offered
patients the eye drops, because I didn't want to provide medical
care which isn't supported by scientific evidence. When patients
demanded, I explained that they are ineffective, and prescribed
them only when they still demanded. But now, I find myself giv-
ing the drugs to patients without discussion, but hinting, 'It's
good for your eye.' I cannot help but attend to business".
We observed an association between physicians' affilia-
tion and their attitudes toward prescription. Ophthalmol-
ogists who owned private clinics were more likely to
prescribe the drugs automatically or actively, those in
community hospitals were more likely to prescribe them
passively, and those in teaching hospitals were more likely
to delegate the decisions to the patients. However, five
hospital-based physicians prescribed the drug automati-
cally.
Implementation of the guidelines and changes in clinical 
practice
Two ophthalmologists considered the guideline recom-
mendations to be exceedingly vague. When we asked par-
ticipants about guideline implementation, 23 physicians
replied that they had already adopted the recommenda-
tion to "prescribe the drugs with adequate informed con-
sent" prior to reading the guidelines. They had always
explained the uncertain effectiveness of these drops to
patients and prescribed them only to those who still
requested them, thus, their prescription behaviours were
not altered by the guidelines. However, when we asked
participants what they actually say to patients during
informed consent, 31 physicians replied that they usually
touched upon the uncertainty of the drugs' effectiveness.
Ten physicians considered a detailed explanation about
evidence of effectiveness unnecessary because they
believed that patients would neither want nor understand
it:
Ophthalmologist: "I don't tell them everything known in
regard to evidence. Of course, if they had serious side effects or
were proven to be completely ineffective, I would explain that.
But for now, whether the drugs are ineffective has yet to be
determined, and the drug is still approved by the government, I
don't think we have to tell patients what is uncertain".BMC Health Services Research 2006, 6:92 http://www.biomedcentral.com/1472-6963/6/92
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Six physicians interpreted the guidelines as instruction to
not prescribe the drugs. However, these participants had
adopted the guidelines into their practices prior to their
issue. Two of them reported being relieved, since the
guidelines' description of the drugs' effectiveness was con-
sistent with their beliefs. However, one GP, who passively
prescribed the eye drops, pointed out the complexities of
informed consent procedures.
GP: "The phrase 'with adequate informed consent,' which is
used in many Japanese guidelines is very difficult to perform.
Patients with cataract are usually elderly people who prefer
paternalistic treatment and are willing to delegate decisions to
physicians. On top of that, I'm afraid that patients in general
don't understand why these eye drops, which had previously
been judged effective by the government, are now judged inef-
fective by EBM."
Fifteen physicians were questioned by patients about the
effectiveness of the eye drops after encountering media
coverage of the issue. Some discontinued prescribing the
drugs at this point. An ophthalmologist who actively pre-
scribed the drugs mentioned that his patient had reported
believing the drops to be effective regardless of the press
coverage. Consequently, physicians reported that only a
few patients had discontinued the drugs.
EBM and health policy
When we asked participants whether they thought the
coverage of these eye drops by health insurance should be
revoked based on "evidence" of their ineffectiveness,
about one third disagreed with this statement. The pri-
mary reason for this was quite simple; they did not con-
sider such drops to be futile and appreciated the
advantages of using them in their practices, considering
the absence of an alternative drug. Eleven ophthalmolo-
gists were concerned about having to explain to patients
why they had prescribed the drugs for so long if they were
determined to be ineffective and revoked by the govern-
ment. Four physicians were confounded by the discrep-
ancy between the "effectiveness" that was once stated by
the government and then later assessed by EBM. They
experienced embarrassment from the sudden change in
assessment of drug effectiveness by the authority, as this
resulted in the standard treatment they had performed in
good faith being labelled as "scientifically ineffective."
Ophthalmologist: "I have believed these drops to be effective
for a long time. Therefore, I can't accept that they aren't effec-
tive now. I would have preferred that the government approved
the drug with a more adequate review. Physicians as well as
patients were shocked after using the eye drops over a long
period. It's too late say to my patients, 'Recently they turned out
to be ineffective.'"
Ten physicians thought that approval should only be
revoked if the eye drops were proved truly ineffective;
however, they considered it too early to determine effec-
tiveness based on such scarce data. These physicians
stressed the necessity of conducting large clinical trials to
investigate the "true effectiveness" of these drugs, and
thereby obtain "consent" from all physicians to revoke
approval. One ophthalmologist expressed her distrust of
the government's attitude toward the approval and recent
reassessment of the drug's effectiveness without scruples:
Ophthalmologist: "Why did the government approve the
drugs before they correctly evaluated their effectiveness?
Although those who made the approval decision are to blame,
the guideline was issued in such a manner that the government
does not claim any responsibility; consequently patients blame
physicians for this policy."
Discussion
This study aimed to identify how the practices of ophthal-
mologists and GPs are influenced by so-called "scientific
evidence." We selected the recommendations regarding
eye drop treatment (as contained in the Evidence-based
Guidelines for Cataract Treatment) as a research topic for
the following reasons. First, these medications are greatly
accepted among the general public in Japan, recom-
mended by many medical texts as the standard of care for
cataracts, and are also covered by national health insur-
ance. Second, physicians' perceptions of the effectiveness
of these drugs and how evidence has changed these per-
ceptions are not well known. Third, prescribing the drugs
brings obvious economic benefits to providers under the
fee-for-service payment system in Japan. Although the
drugs themselves are inexpensive (around 200 yen
($1.90) for a 15 ml bottle), patients who consult doctors
to refill prescriptions often concurrently receive routine
medical check-ups, which elevates the total expenditure
associated with the prescription of eye drops. Fourth,
these drugs have considerable economic impact on
Japan's healthcare system. The annual domestic sales are
approximately 18 billion yen ($176 million) [14], and
cataract-related outpatient care was estimated to cost the
nation approximately 78 billion yen ($743 million) in
2002 [15]. Lastly, despite the guidelines, the government
still approves the coverage of these drugs under the
national health insurance plan.
Several studies have investigated the reasons why physi-
cians sometimes provide treatment with marginal effec-
tiveness. Butler et al. investigated the reasons why GPs
prescribe antibiotics for a sore throat despite the lack of
evidence supporting this practice. They concluded that
although doctors know that antibiotics do not help most
sore throat sufferers and find prescribing "against the evi-
dence" uncomfortable, they try not to jeopardise relation-BMC Health Services Research 2006, 6:92 http://www.biomedcentral.com/1472-6963/6/92
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ships with patients over this issue [16]. They also argued
that consistent evidence for a lack of effectiveness is
unlikely to change physicians' prescribing practices. Con-
versely, Kumar et al. argued that GPs are mostly comfort-
able with their prescribing decisions; therefore,
maintaining favourable physician-patient relations is not
the primary objective of their prescribing practices [17].
However, in these particular studies, the influence of sci-
entific evidence on changes in physicians' practices has
never been compared with those of economic incentives,
standard of care expectations of both physicians and
patients, and authority approval.
Rationale for prescribing
This study revealed that despite their extensive use, very
few physicians prescribed the eye drops with expectations
that any objective signs of clinical effectiveness would
result. Nevertheless, few physicians agreed that the drugs
lack effectiveness. On the surface, it seems paradoxical
that physicians assert the effectiveness of the eye drops
while simultaneously denouncing the objective effective-
ness of these drugs. The best possible explanation for this
contradiction is that effectiveness itself is not an essential
factor in a physician's decision to write a prescription; for
most physicians, the effectiveness of the eye drops did not
necessarily need to bring remarkable clinical benefits to
patients.
Physicians believed that prescribing eye drops was the eas-
iest and most secure method of satisfying patients. When
patients complained of decreased visual acuity and
expected eye drops, many physicians felt uneasy sending
them home empty-handed. Although physicians cited
patients' requests as the main reason for prescribing the
eye drops, they were not always concerned whether
patients truly wanted them. Physicians seldom considered
that prescribing might disadvantage patients; on the con-
trary, they were concerned that patients would not appre-
ciate physicians who gave a complicated explanation of
EBM instead of prescribing the eye drops. Therefore, even
though physicians were not uncomfortable with provid-
ing treatment that is not supported by evidence, they did
express discomfort with guidelines that contradict their
actions.
The validity of the prescription, including the risks and
benefits of daily use of the eye drops, was seldom dis-
cussed between physicians and patients. One possible rea-
son for this is that physicians felt that doing so would be
time consuming and unrewarding for the patient [16].
Japanese medical settings are particularly unfit for
demanding encounters with patients. In fact, because
patients have free access to all medical institutions, they
often have to wait three hours for a three-minute consul-
tation [18]. Another possible reason is that physicians do
not have firm convictions about the ineffectiveness of the
eye drops. Before the guidelines were issued, most physi-
cians had prescribed the eye drops without giving much
thought to their effectiveness, with the only criterion
being permission from the government to cover the drugs
under the national health insurance system. Although one
physician suggested that patients are willing to take advice
from a physician to avoid useless drugs, others believed
that patients were more likely to be satisfied when they
used the eye drops.
Physicians also acknowledged the various benefits of pre-
scribing drugs that outweigh their uncertain effectiveness.
These included enhancement of the doctor-patient rela-
tionship by improving patient satisfaction and psycholog-
ical comfort, as well as believing that they were providing
satisfactory medical treatment to patients. Economic ben-
efit was also cited as a sensible reason for prescription. In
the Japanese universal health insurance system, enrol-
ment is mandatory and all reimbursements to providers
are paid on a fee-for-service basis. Payments made by
patients out-of-pocket are quite low since drugs are fully
covered by the insurance. Therefore, physicians are free to
make treatment decisions without worrying about the
patient's ability to pay. A cultural aversion to invasive pro-
cedures may also explain why both physicians and
patients prefer conservative treatment such as eye drops,
rather than surgical treatment.
Some readers may be apprehensive about whether there is
an excess of patients who request unnecessary medica-
tions. Our study did not clarify whether physicians or
patients took the lead in establishing this pattern, nor
could we find additional studies regarding patients'
beliefs and attitudes toward eye drops Previous studies
have revealed that physicians' perceptions of patient
expectations are the strongest predictors of prescription
decisions [16,19,20]. Britten and Ukoumunne found that
physicians wrote a prescription to patients who seemed to
want one even when they considered it to be clinically
unnecessary [20]. In their study, 22% of prescriptions by
GPs were not strictly indicated on medical grounds. Simi-
larly, Scott et al have investigated the ways in which
patients pressure physicians into prescribing antibiotics
for respiratory infections. Their study found that,
although physicians prescribed an antibiotic to roughly
68% of patients with an acute respiratory infection,
approximately 80% of prescriptions were influenced by
patient pressure and considered to be clinically unneces-
sary [21]. Our findings showed this same propensity for
physicians to prescribe as a means to satisfy patient
wishes. Interestingly enough, this contrast sharply with
the common belief that Japanese physicians are paternal-
istic [22]. Our findings showed that patients' opinions
were often more relevant than clinical necessity when pre-BMC Health Services Research 2006, 6:92 http://www.biomedcentral.com/1472-6963/6/92
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scribing eye drops. Such a strong appreciation of medica-
tion by both physicians and patients may originate from
the tradition of ancient Japanese medicine, in which med-
ication was the primary treatment and medical practition-
ers were often considered to be pharmacists [23].
Our study suggests the possibility of changing physicians'
prescription behaviours through increasing patients'
awareness of scientific evidence. Most guidelines in Japan
are solely intended for physician use. When patients begin
to appreciate physicians who make an effort to provide
evidence-supported medical care, it is likely that physi-
cians will change their prescription behaviours. Further
approaches to clinical guidelines should focus on how to
make clinical decisions with the active involvement of
patients. Economic incentives for evidence-based medical
care are also important in changing physician practices.
Unfortunately, the current fee-for-service payment system
brings obvious economic disadvantages to providers who
limit the number of prescriptions.
We must consider what healthcare provides for patients;
namely, does it only provide medical care supported by
scientific evidence, or does it also provide psychological
comfort to patients (rather difficult to assess by EBM)?
Our study focused on physicians' prescribing behaviours
related to drugs that lack evidence of effectiveness." There-
fore, the findings may not be applicable to other drugs
with considerable evidence of effectiveness; however,
many drugs with marginal evidence of effectiveness are
currently prescribed in Japan. Although our study does
not answer the question of whether evidence-based
healthcare and treatment is superior to treatment with
marginal effects, both physicians and patients should con-
sider what constitutes the integrity of medical care. Even
though the prescription of drugs with marginal effects is a
convenient tool for maintaining good physician-patient
relations, such an easily obtainable prescription may com-
promise the quality of medical care in terms of practical-
ity, utilization, and the balance between risks and
benefits. Japan's health care system should be designed so
that it does not conflict with quality medical care.
Conclusion
Occasionally physicians prescribe drugs without expect-
ing remarkable effectiveness. In such cases, evidence of
effectiveness seldom changes their clinical practices or
prescribing behaviours. Cataract eye drops are a typical
illustration of this phenomenon. Many determinants
influence physicians' prescribing behaviours. The effec-
tiveness of a drug assessed by the EBM paradigm is only
one such consideration. For physicians to change their
practices according to evidence-based guidelines, they
must recognize, and understand, and agree with the evi-
dence, feel confident about their abilities, and overcome
the inertia of previous practices [24]. The absence of any
one of these components could prevent the evidence from
taking root in physicians' clinical practices. It is proposed
that they are more likely to alter such patterns when the
change results in better patient outcomes. Unfortunately,
discontinuing the prescription of these eye drops does not
currently seem to be a desirable option for either physi-
cians or patients. These findings support the hypothesis
that replicated scientific evidence alone does not easily
change physician behaviours [16], unless evidence-sup-
ported clinical practices are accepted by the general public
and supported by health policies.
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Appendix
Recommendation of the Evidence-based Clinical
Guideline for Cataract Treatment:
Physicians can consider prescribing eye drops for patients
with early stage senile cataract. Since there is no scientific
evidence supporting the effectiveness of these drugs, it is
desirable to give patients the drugs with adequate
informed consent. (Grade of Recommendation: level C)
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